ReportsnReports | Epidemiology: Peripheral Neuropathic Pain – A common co-morbidity for HIV, diabetes, and herpes zoster
Browse All : Market Research Reports Introduction The prevalence of neuropathic pain is estimated at approximately 10% in the adult population of the US, and is likely to be the same in other developed countries. Peripheral neuropathic pain is a common co-morbidity in HIV, diabetes, and herpes zoster; it affects approximately 22% of HIV-positive individuals, 6% of type 1 diabetics, 18% of type 2 diabetics, and 6–18% of herpes zoster cases. Features and benefits: Gain insight into market potential, including a robust 10-year epidemiology forecast of neuropathic pain cases in HIV, diabetes, and herpes zoster. Understand the key epidemiologic risk factors associated with peripheral neuropathic pain in HIV, diabetes, and herpes zoster. Highlights During 2010, Datamonitor estimates that 239,700 diagnosed, prevalent HIV cases with peripheral neuropathic pain existed in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). Between 2010 and 2020, Datamonitor forecasts these cases to increase by 17% in the seven major markets, resulting in 279,900 cases in 2020. Among the diagnosed diabetic population in 2010, Datamonitor estimates that 128,500 and 5.59 million prevalent types 1 and 2 diabetes cases with diabetic peripheral neuropathic pain (DPNP), respectively, existed in the seven major markets. Between 2010 and 2020, Datamonitor forecasts both diabetes types 1 and 2 DPNP cases to increase by 14%. During 2010, Datamonitor estimates that 249,000 diagnosed, incident post-herpetic neuralgia cases existed in the seven major markets. Between 2010 and 2020, Datamonitor forecasts these cases to increase by 16% in the seven major markets, resulting in 288,000 cases in 2020. See More : Epidemiology Peripheral Neuropathic Pain Table Of Contents OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Disease burden overview Peripheral neuropathic pain in HIV Peripheral neuropathic pain in diabetes Post-herpetic neuralgia Forecast results, 2010–20 Peripheral neuropathic pain in HIV
Peripheral neuropathic pain in diabetes Post-herpetic neuralgia DISEASE DEFINITION AND DIAGNOSTIC CRITERIA Etiological descriptions of peripheral neuropathic pain Peripheral neuropathic pain in HIV Peripheral neuropathic pain in diabetes Post-herpetic neuralgia Diagnosis of and testing for peripheral neuropathic pain in HIV Diagnosis of and testing for peripheral neuropathic pain in diabetes Diagnosis of and testing for post-herpetic neuralgia Classification of peripheral neuropathic pain in HIV, diabetes, and post-herpetic neuralgia Peripheral neuropathic pain in diabetes Post-herpetic neuralgia GLOBAL VARIATION AND HISTORICAL TRENDS Global variation and historical trends Peripheral neuropathic pain in HIV Peripheral neuropathic pain in diabetes Post-herpetic neuralgia DRIVERS OF DISEASE EPIDEMIOLOGY Risk factors for peripheral neuropathic pain in HIV/AIDS Nucleoside reverse transcriptase inhibitors HIV positivity time length and AIDS status Age Gender Risk factors for peripheral neuropathic pain in diabetes Disease duration Age Diabetes type HDL cholesterol Risk factors for post-herpetic neuralgia Age Gender Immunologically compromised status Co-morbid conditions Peripheral neuropathic pain in diabetes EPIDEMIOLOGIC FORECASTING OF PERIPHERAL NEUROPATHIC PAIN Overview Population denominators Subpopulations Diabetic peripheral neuropathic pain Post-herpetic neuralgia US Sources used Methods Sources not used Japan Sources used Methods Sources not used France
Sources used Methods Sources not used Germany Sources used Methods Sources not used Italy Sources used Methods Sources not used Spain Sources used Methods Sources not used UK Sources used Methods Sources not used EPIDEMIOLOGIC RESULTS Estimated diagnosed, prevalent cases of HIV with peripheral neuropathic pain and future trends Age and gender segmentation Age-standardized prevalent (and/or incident) rates Estimated diagnosed, prevalent cases of diabetes types 1 and 2 with peripheral neuropathic pain and future trends Age and gender segmentation Age-standardized prevalent (and/or incident) rates Estimated diagnosed, incident post-herpetic neuralgia cases and future trends Segmentation by age group Segmentation by gender DISCUSSION Peripheral neuropathic pain in HIV Strengths and limits of Datamonitor’s epidemiologic projections Peripheral neuropathic pain in diabetes Strengths and limits of Datamonitor’s epidemiologic projections Post-herpetic neuralgia Strengths and limits of Datamonitor’s epidemiologic projections LIST OF TABLES Table: International Association for the Study of Pain taxonomy for pain conditions Table: Key aspects in diagnosing peripheral neuropathic pain in diabetes Table: ICD-10 codes relevant to peripheral neuropathic pain in HIV, diabetes, and post-herpetic neuralgia Table: Classification systems for diabetic neuropathies Table: Neuropathic pain prevalence according to population-based studies Table: Peripheral neuropathy and neuropathic pain prevalence among HIV cases Table: Peripheral neuropathy and neuropathic pain prevalence among diabetes cases Table: Herpes zoster and post-herpetic neuralgia burden in various countries Table: HIV and AIDS data sources in the seven major markets used in this analysis
Table: Summary of sources used in analyses of type 2 diabetes mellitus, published between 1999 and 2009 Table: Diagnosed prevalent cases of HIV with peripheral neuropathic pain across all ages in the seven major markets, 2010–20 Table: Diagnosed prevalent cases of type 1 diabetes with peripheral neuropathic pain in those aged 20–79 in the seven major markets, 2010–20 Table: Diagnosed prevalent cases of type 2 diabetes with peripheral neuropathic pain in those aged 20–79 in the seven major markets (000s), 2010–20 Table: Diagnosed, incident post-herpetic neuralgia cases in those aged 20 years and older in the seven major markets, 2010–20 Table: Diagnosed, incident post-herpetic neuralgia cases in those aged 20 years and older in the seven major markets, segmented by age group, 2010–20 Table: Diagnosed, incident post-herpetic neuralgia cases in those aged 20 years and older in the seven major markets, segmented by gender, 2010–20 LIST OF FIGURES Figure: Age-adjusted post-herpetic neuralgia incidence in men at least 20 years of age (per 100,000), 2010 Figure: Age-adjusted post-herpetic neuralgia incidence in women at least 20 years of age (per 100,000), 2010 Related Market Research Reports:
Market and Product Forecasts: Targeted Cancer Therapies - Trend towards personalized medicine will lead to market fragmentation Epidemiology: Peripheral Neuropathic Pain – A common co-morbidity for HIV, diabetes, and herpes zoster Epidemiology: Influenza – Incident cases expected to remain stable due to low vaccination rates The Future of Skincare: Consumption trends and product preferences Express Benchmarking 2011 – Belgium Express Benchmarking 2011 – Finland Express Benchmarking 2011 – Germany Express Benchmarking 2011 – the Netherlands Express Benchmarking 2011 – Italy Express Benchmarking 2011- France Express Benchmarking 2011 – Austria Express Benchmarking 2011 – Czech Republic About Us: ReportsnReports is an online library of over 75,000 market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports. Follow us on Twitter: http://twitter.com/marketsreports Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689 Contact: Mr. Priyank 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: + 1 888 391 5441 E-mail: sales@reportsandreports.com http://www.reportsnreports.com Visit Our Blog : Market Research Reports